This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Critical questions answered by this Study:
# Where will these developments take the industry in the mid-to-long term?
# Who are the major end users in the apheresis market, and what are the benefits they avail by implementing apheresis technology?
# What are the recent trends in the apheresis market?
# What are the major market dynamics and their impact on overall market growth?
# What is the global scenario of the apheresis market?
The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.
Download PDF Brochure@
The market for apheresis is primarily driven by the rising prevalence of chronic diseases and the growing number of trauma and injury cases, the increasing demand for source plasma from biopharmaceutical companies, the rising demand for blood components and growing concerns regarding blood safety, the increase in the number of complex surgical procedures, and the favorable reimbursement for apheresis procedures.
However, the high cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through the rental model, fewer blood donations using apheresis due to lack of awareness, and the stringent donor recruitment criteria are factors expected to limit market growth to a certain extent in the coming years.
Objectives of the Study:
# To define, describe, and forecast the global apheresis market by product, technology, application, procedure, end user, and region
# To provide detailed information about the factors influencing the market growth (drivers, restraints, opportunities, and challenges)
# To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
# To forecast the size of the apheresis market in five regions (along with major countries)—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
# To profile key players in the apheresis market and comprehensively analyze their core competencies and market shares
# To track and analyze competitive developments such as acquisitions; new product launches; collaborations, partnerships, and agreements; and R&D activities of the leading players in the global apheresis market
North America accounted for the largest market share in 2018
North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.
Request Sample Pages@
Recent Developments:
# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.
# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.
# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (China). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.
# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.
The prominent players in this market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co. Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Medicap Clinic GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed (Switzerland), Cytosorbents Corporation (US), and Toray Medical Co. Ltd. (Japan), among other key players.
No comments:
Post a Comment